Monitoring the efficacy of artemether-lumefantrine for the treatment of uncomplicated malaria in Malawian children

Rosalia Dambe1*, John Sande2, Doreen Ali2, Ben Chilima3, Wilfred Dodoli4, Charles Michelo1, Grace Malenga2 and Kamija S Phiri5

Abstract

**Background:** The resistance of malaria parasites to sulphadoxine-pyrimethamine (SP) in 2007 led to the Malawi Ministry of Health changing to artemether-lumefantrine (AL) as first-line for uncomplicated malaria treatment. This study determined the efficacy and safety of AL for the treatment of uncomplicated *Plasmodium falciparum* malaria among six to 59 months old Malawian children.

**Methods:** This was a prospective study of children six to 59 months old treated with AL after presenting with uncomplicated malaria in the six health facilities in Malawi. The children were followed up on days 1, 2, 3, 7, 14, 21 and 28 days post-treatment and assessed for clinical and parasitological responses. The Kaplan Meier survival estimate was used to measure the efficacy of AL by calculating the cumulative risk of failure at day 28.

**Results:** A total of 322 children were recruited into the study across the six sites. The overall intention-to-treat (ITT) polymerase chain reaction (PCR)-corrected cure rate was 93.4%. Per protocol overall PCR-corrected cure rates for the study sites were; Karonga 98.0%, Kawale 97.4%, Machinga 90.2%, Mangochi 95.4% and Rumphi 91.3%. Nkhotakota study site had the lowest cure rate of 78.0%.

**Conclusions:** There is evidence of good efficacy of AL in Malawi notwithstanding geographical contrasts and this supports the continued use of AL as the first-line treatment for uncomplicated malaria. However there may be need to further investigate the comparatively low efficacy rate found in Nkhotakota district in order to identify possible determinants of treatment failure.

**Keywords:** Malawi, Artemether-lumefantrine, Children, Uncomplicated malaria, Efficacy

**Background**

Malaria is still one of the leading causes of mortality among children under five years of age in sub-Saharan Africa despite efforts to control it [1,2]. Globally deaths due to malaria were estimated at 584 000 with an uncertainty range of 367 000 to 755 000 in 2013 [3]. The prevalence of malaria was 28% among six to 59 months old children in Malawi [4]. Prevention and control of malaria is important in the reduction of malaria burden in Malawi. The Malawi malaria strategic plan for the years 2011 to 2015 aims at moving towards universal coverage of malaria interventions [5]. Malaria is included in the Malawi Millennium Development Goal (MDG) number 6, whose target is to stop and begin to reverse the incidence of malaria and other major diseases by 2015 [6,7].

The World Health Organization (WHO) recommended the use of artemisinin-based combination therapy (ACT) for treatment of uncomplicated malaria [8]. The current first-line fixed dose ACT is presumed to be active against all forms of *Plasmodium* [9,10], including artemether-lumefantrine (AL), artesunate-amodiaquine, artesunate-mefloquine, and artesunate plus sulphadoxine-pyrimethamine (SP). Malawi Ministry of Health changed to AL as first-line drug for uncomplicated malaria treatment based on SP resistance in 2007 [11]. Evidence from...
other countries show high efficacy and safety of AL [12,13]. However, there has been evidence of resistance to ACT in countries of greater Mekong sub-region [14-16]. Delayed parasite clearance is a sign of artemisinin resistance [17]. Passive surveillance systems are a basis for detection and gathering epidemiological data among countries that are aiming at malaria disease control [18]. Sentinel site monitoring and surveillance of anti-malarial drug efficacy every 24 months assists containment of resistance of malaria parasite to ACT. The WHO recommends conducting research in resistance to ACT for proper management and understanding of the resistance [14]. The study was conducted to determine AL efficacy and safety for the treatment of uncomplicated Plasmodium falciparum malaria among Malawian children aged between six to 59 months.

Methods
Study design and setting
This was a prospective study conducted between the months of March to June 2010 aimed at monitoring the efficacy and safety of AL for the treatment of uncomplicated P. falciparum malaria in Malawian children. Malawi is in south-eastern Africa. The climate is tropical-continental with some maritime influences and a rainy season varying between November and April. Malaria is endemic in Malawi, with a prevalence of 28% among children under five years of age [4]. The study took place in Malawi at the following study sites: Rumphi, Mangochi, Nkhotakota, Machinga, Lilongwe and Karonga. Children six to 59 months old, presenting with uncomplicated P. falciparum malaria at the health centre in the selected study sites were recruited in the study.

Participant recruitment and follow up
Study participants were screened as they presented to the health facility. The inclusion criteria for the study were: children aged from six to 59 months, presence of mono-infection with P. falciparum detected by microscopy with parasite density of 1,000 - 200,000/μl asexual forms, axillary temperature ≥37.5 °C or history of fever for the previous 24 hours, guardians willing to return for weekly routine and unscheduled visits, planning to remain in the study area during the study and provided informed consent. The exclusion criteria for the study were: presence of general danger signs or severe P. falciparum malaria in the children as per WHO classification, mixed or mono-infection with other Plasmodium species, severe malnutrition (child growth standard below ~3 z-score, or symmetrical oedema involving the feet or mid-upper arm circumference <110 mm), other diseases like measles, acute lower respiratory tract infection, severe diarrhoea with dehydration, cardiac, renal and hepatic diseases. Further exclusion included regular medication, which might have interfered with anti-malarial drugs pharmacokinetics and history of contraindications or hypersensitivity reactions to AL. Assuming that treatment failure rate of AL in Malawi will be about 5%. At a confidence level of 95% and a precision around the estimate of 5%, a minimum of 73 patients were to be included. With a design effect of 2.0, a number of 146 participants were reached. All children were treated with AL. Regular tablets of AL (Coartem®, Novartis) were administered orally according to weight bands using a standard dose of 2mg/kg artemether with 10mg/kg lumefantrine (co-formulated tablets) twice daily on Days 0, 1 and 2 [8]. All six doses were directly observed by a research nurse or clinician. If a patient vomited twice within 30 minutes, he or she would receive 10mg (0.2ml) of quinine per kg body weight as determined by the clinician according to the national treatment guidelines.

The study was conducted for a period of 28 days. Day 0 was designed as the day patients were enrolled and received the first dose of AL. Follow up was from Day 1, 2, 3, 7, 14, 21 and 28. During the follow up visits, children had clinical and laboratory assessments done. Haemoglobin was determined using a Hemocue®. Thick and thin blood smears were prepared for determination of malaria parasitaemia. Smears were double read and if any discrepancies between the two readers, the slide was read by a third person independently. PCR analysis was conducted at the Malawi Liverpool Wellcome Trust laboratories, which provided a PCR-corrected outcome.

Guardians of participants were advised to return on any day during the follow-up period if symptoms recurred or became severe, or any occurrence of adverse events. International Conference on Harmonization (ICH) Tripartite Guideline for 2003 defines an adverse event as “any untoward medical occurrence in a patient administered a medicinal product and which does not necessarily have to have a causal relationship with this treatment” [19].

Outcomes of the study
The primary outcomes for the study were overall treatment success and overall treatment failure. Treatment outcomes were classified according to WHO guidelines as; early treatment failure (ETF), late clinical failure (LCF), late parasitological failure (LPF), loss to follow-up, withdrawal from the study and adequate clinical and parasitological response (ACPR) [20]. The secondary outcomes were gametocyte carriage, parasitaemia and fever.
Data management and statistical analysis
Data was collected on paper using a Case Report Form (CRF). These were checked on a daily basis before data entry. Then the data was independently double entered into an Excel database specifically designed by the WHO for anti-malarial efficacy studies. Data was then exported and analysed in STATA. Both intention to treat analysis and per protocol analysis methods were used when analysing the data. Intention to treat analysis estimated the effect of the assigned treatment (AL). Per protocol analysis estimated the effect of adhering to the assigned treatment protocol. A description of baseline characteristics of all participants involved in the study was presented. The Kaplan Meier method was used to measure the efficacy of AL by calculating the cumulative risk of failure at day 28. There was comparison among the study sites Rumphi, Mangochi, Nkhotakota, Machinga, Kawale, and Karonga on: the proportion of lost to follow up patients and those patients withdrawn from the study, proportion of ETF, LCF, LPF, ACPR on day 28, success and failure cumulative incidence rates on day 28 with 95% confidence interval and p value of less than 0.05 was considered significant. The differences in efficacy between sites were assessed using Cox proportional hazards model.

Ethical consideration
This study was approved by the National Health Sciences Research Committee (Protocol Approval number: NHSRC/725) in Malawi.

Results
Baseline characteristics
An overall number of 322 participants were recruited into the study. Intention to treat analysis included loss to follow up and withdrawals in the denominator while per protocol analysis excluded participants withdrawn 16.2% (52/322) and lost to follow up 2.5% (8/322) from the study. Table 1 shows the baseline characteristics of the study participants. The female participants were 50.3% (162/322). The overall mean weight was 11.4 kg (SD 2.7 kg). The overall mean height was 75 cm (SD 22.6 cm). The mean temperature at recruitment on day 0 was 38.5 degrees Celsius (SD 1.2 degrees Celsius). In the study, four participants were recruited above the inclusion criteria parasite density of 200,000 but were included in the analysis as these children (above limit) did not present with any other WHO criteria for severe malaria. Parasite density showed median of 33,080 (interquartile range 12,810 – 76,980 μ/mL).

Temperature and parasite clearance
All 322 children presented with fever during recruitment into the study with the mean temperature of 38.5°C. All 322 children reported with parasitaemia at recruitment on Day 0. Day 1 reported 68.1% (211/310) children who had not cleared parasites, while Day 2 had 9.1% (28/305) children with parasitaemia. Day 3 had 0.9% (3/305) children reporting with parasitaemia. Figure 1 shows mean parasitaemia median (IQR) among all study sites. Parasite clearance median (IQR) 2 was 76,980 (162/322).

Table 1 Baseline characteristics of the study participants of efficacy of AL study among Malawian children

| Characteristic          | Study population1 |
|-------------------------|-------------------|
| Sex                     |                   |
| Female                  | 50.3% (162/322)   |
| Male                    | 49.6% (160/322)   |
| Age (months)2           | 27.6 (14.3)       |
| Weight (kg) 2           | 11.4 (2.7)        |
| Height (cm)2            | 74.9 (22.6)       |
| Temperature °C3         | 38.5 (1.2)        |
| Parasitaemia median (IQR)4 | 33,080 (12,810 – 76,980) |
| Gametocyte carriage     | 2.1% (7/322)      |

Notes: 1n = 322; 2Mean (standard deviation); 3At enrolment into the study mean (standard deviation); 4Median (Inter-quartile range)Per micro mil at enrolment.

Efficacy of AL
All participants who presented with malaria during the follow-up period had their filter paper sample undergo PCR. The PCR-corrected cure rates were measured. Using intention to treat analysis, ETF was reported among 1.6% (5/320) study participants. LPF was reported among 0.9% (3/320) study participants while LCF was reported among 4.1% (13/320) study participants during the 28 days follow up period. This makes a total of 21 children with treatment failure and total time at risk of 7,926 days. The incident rate (hazard function) was estimated as 2.65 per 1,000 persons per day with the assumption that the incident rate remains constant. Intention-to-treat Kaplan-Meier survival estimate curve is displayed in Figure 2 and the ACPR proportion was 0.934.

Efficacy of AL by study site
The treatment outcomes by study site were as follows; Nkhotakota study site had the highest LCF of 6, while Machinga study site had 3 LCF and Karonga had 0 LCF. Karonga, Machinga and Nkhotakota study sites showed one child with ETF in each study site while Kawale and Mangochi had no children observed to ETF. There were three children with LPF, one in Mangochi and two in Nkhotakota which were confirmed by PCR (Table 2). Table 3 shows the adjusted hazard ratios; Nkhotakota study site risk of treatment failure was significantly higher as compared to Karonga study site.
Gametocyte carriage
Gametocytes were found in peripheral blood of seven children at recruitment into the study. One child each was found with gametocytes on Day 7 and 21. No gametocyte carriage was reported on any other follow-up day.

Occurrence of adverse events
A number of adverse events occurred during the 28 day follow-up period however none of the events were related to the effect of AL (Figure 3). The most common occurring adverse events were upper respiratory tract infection (URTI) and pneumonia.
Discussion
The study showed that the overall efficacy of AL after PCR correction was high in Malawi at 93.4%. This corresponds with other studies done in other countries of Africa on the efficacy of AL [12,13,21,22]. A study done in Ethiopia, although it had a slightly different study design and the follow up period was up to 42 days [21] as compared to the 28 days follow up in this study, had comparable findings. Correction by PCR enables differentiation between recurrence and recrudescence of the initial infection from re-infection. This present study showed that there were a few treatment failures, although most of them were re-infections as opposed to recrudescence. This is of particular concern in areas with very intense malaria transmission where anti-malarial drugs with longer half-life may offer the advantage of preventing re-infection but also be a target for drug resistance development. The very low efficacy rate observed in Nkhotakota is of particular concern. It is clear that this is a site with intense malaria transmission and where other malaria interventions have been carried out. Treatment failure is when malaria parasites fail to clear and malaria clinical symptoms fail to be cured even though anti-malarial drugs have been taken [14]. It can be influenced by several factors more often a decrease in drug concentrations [23]. A limitation of this study was the unavailability of lumefantrine levels on Day 7 which would help further clarify reasons for some of the treatment failures, as there are many other factors that may cause poor absorption of the drugs hence decreasing the bioavailability of AL in the blood. The other limitation was the power of the study; this study was underpowered for site specific analysis.

Table 2 Treatment outcomes by study site

| Outcome | Study site | Karonga | Kawale | Machinga | Mangochi | Nkhotakota | Rumphi |
|---------|------------|---------|--------|----------|----------|------------|--------|
| ACPR²  | n = 52     | 49      | 38     | 37       | 41       | 32         | 42     |
| ETF³   | n = 54     | 1       | 0      | 1        | 0        | 1          | 2      |
| LCF⁴   | n = 55     | 0       | 1      | 3        | 1        | 6          | 2      |
| LPF⁵   | n = 49     | 0       | 0      | 0        | 1        | 2          | 0      |
| LFU⁶   | n = 53     | 1       | 2      | 1        | 2        | 1          | 1      |
| WTH⁷   | n = 7      | 1       | 13     | 13       | 12       | 7          | 6      |

Table 3 Risk of treatment failure in six study sites adjusted for age and sex

| Characteristic | PCR-corrected cure rate | Hazard ratio¹ | P value |
|---------------|-------------------------|---------------|---------|
| Age group(months) |                         |               |         |
| 6 - 12 | 86.5% (32/37) | 1 | - |
| 13 - 24 | 91.1% (82/90) | 0.79 (0.25, 2.46) | 0.680 |
| 25 - 36 | 94.1% (48/51) | 0.46 (0.11, 1.95) | 0.289 |
| 37 - 59 | 93.7% (74/79) | 0.50 (0.14, 1.76) | 0.283 |
| Sex |                         |               |         |
| Female | 90.5% (114/126) | 1 | - |
| Male | 93.3% (125/134) | 0.71 (0.30, 1.72) | 0.457 |
| Study site |                         |               |         |
| Karonga | 98.0% (49/50) | 1 | - |
| Kawale | 97.4% (38/39) | 1.25 (0.08, 20.28) | 0.873 |
| Machinga | 90.2% (37/41) | 4.76 (0.52, 43.34) | 0.166 |
| Mangochi | 97.4% (41/43) | 2.08 (0.19, 23.16) | 0.550 |
| Nkhotakota | 78.1% (32/41) | 10.60 (1.33, 83.04) | 0.025 |
| Rumphi | 91.3% (42/46) | 4.33 (0.48, 39.03) | 0.191 |

¹Tested by Cox regression (95% Confidence Interval).
There was a dramatic reduction in parasitaemia in the study participants after only one day’s dose of AL. This is consistent with other studies that have shown that the artemisinin derivative act more rapidly than other types of anti-malarial, both in killing parasites and in inhibiting their major metabolic processes, such as glycolysis, nucleic acid and protein synthesis [24]. They also attack the broadest age range of parasites, from the smallest rings that have recently invaded erythrocytes to more mature stages of parasites such as developing trophozoites and schizonts [24,25]. Their relatively broad stage-specificity of action extends to an ability to impede the development of gametocytes [26]. This contrasts with some other widely used anti-malarial classes such as the 4-aminoquinolines or anti-folates, which do not have the potential to interrupt transmission of malaria. Furthermore, artemisinin drugs inhibit the ability of maturing parasites to make the red cell surface sticky (cytoadherence to endothelial cells) much more effectively than most other anti-malarial drugs [27]. Adverse events reported during the study period were not related to the effect of AL hence did not show serious drug reactions which might have made AL unsafe to take.

The recommendations for the WHO malaria treatment guidelines in the year 2010 emphasises on switching to another anti-malarial drug when the first-line has more than a 10% overall failure rate [8]. Even though Malawi has not yet reached the 10% mark, resistance to artemisinin was discovered along the Thailand–Myanmar border eight years back [28]. A study conducted among adults and children observed that AL was still efficacious in Southern Laos but increased significant rates of recrudescence were observed among the children [29]. The high failure rate for Nkhotakota study site is of concern. The Ministry of Health should continue monitoring AL efficacy and anti-malarial drug resistance in sentinel surveillance sites.

At policy level, AL should remain to be used as first-line treatment for the treatment of uncomplicated P. falciparum malaria in Malawi since the study has demonstrated that AL is safe and has not exceeded the more than 10% cut-off failure rate.

**Conclusion**

This study aimed at determining whether AL was efficacious and safe, and investigated the difference in efficacy between the study sites. The findings of the study showed that there was high efficacy of AL in Malawi. Therefore, it is important to monitor efficacy in order to detect and prevent resistance of AL. Surveillance of the established sentinel sites should continue. However there may be need to further investigate the comparatively low efficacy rate found in Nkhotakota district in order to identify possible determinants of treatment failure. Therefore, AL should remain the first-line treatment for uncomplicated malaria among children in Malawi.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

KP, JS, DA, BC and GM contributed to the study design and data collection. RD analysed the data and prepared the first manuscript draft. All authors contributed to the write-up. All authors read and approved the final manuscript.

Figure 3 Adverse events among children during the 28 days study period.
Acknowledgements

The research team would like to acknowledge Dr Jacqui Montgomery from Malawi Liverpool Wellcome Trust Research Programme, College of Medicine for carrying out the PCR analysis in a very timely fashion. Special thanks to Dr Storm Kabulului and Prof Malcolm Molyneux for their advice and recommendations and John Chiphaeywa from the National Malaria Control Programme for assisting in coordination of the study. Special appreciation should go to Mr Chiwaula and the National Public Health Reference Laboratory and Health Technical Support Services, Ministry of Health who carried out all the laboratory analyses. Acknowledgement must also go to the District Health Officers of the study sites from the Ministry of Health, Malawi, for hosting the study. Thanks also to support from Norwegian Agency for Development Cooperation (NORAD’s) Programme for Master Studies (NOWA), Project number NOWA-2010/1/2841 for their support to RD. Lastly we would like to extend our gratitude to the children and the families that took part in this important study. This study was funded by the Malawi Ministry of Health.

Author details

1 Department of Public Health, School of Medicine, University of Zambia, P.O. Box 50110, Lusaka, Zambia. 2 National Malaria Control Programme, Ministry of Health, Private Bag 65, Lilongwe, Malawi. 3 National Public Health Reference Laboratory Ministry of Health, Private Bag 65, Lilongwe, Malawi. 4 World Health Organization, P.O. Box 30390, Lilongwe, Malawi. 5 Department of Public Health, College of Medicine, University of Malawi, Private Bag 360, Blantyre, Malawi.

Received: 17 October 2014 Accepted: 16 April 2015
Published online: 23 April 2015

References

1. Houeto D, D’Hoore W, Ouendo E, Charlier D, Deccache A. Malaria control among children under five in sub-Saharan Africa: the role of empowerment and parents’ participation besides the clinical strategies. Rural Remote Health. 2007;7:840.
2. Schantz-Dunn J, Nour NM. Malaria and pregnancy: a global health perspective. Rev Obstet Gynecol. 2009;2:186–92.
3. WHO. World malaria report 2014. Geneva World Health Organization, Global Malaria Programme, 2014.
4. National Malaria Control Programme (NMCP) [Malawil and ICF International. Malawi Malaria Indicator Survey (MIS) 2012. Lilongwe, Malawi, and Calverton, Maryland, USA: NMCP and ICF International. 2012. http://idsprogram.com/ pub/pdf/MS13/MS13.pdf. Accessed 12 Feb 2015.
5. National Malaria Control Programme Malawi strategic plan 2011–2015. Towards universal access. Community Health Sciences Unit, Ministry of Health Lilongwe. 2010.
6. Ministry of Development Planning and Cooperation: 2010 Malawi Millennium Development Goals Report. Lilongwe, Malawi: Ministry of Development Planning and Cooperation. 2010. http://planpolis3.xjenesco.org/upload/ Malawi/MalawiMDG2010Report.pdf. Accessed 12 Feb 2015.
7. Commonwealth Foundation. A civil society review of progress towards the Millennium Development Goals in Commonwealth countries. National Report. Malawi: Commonwealth Foundation; 2013. http://www.commonwealthfoundation.com/sites/cwf/files/downloads/ MDG%20Reports%20Malawi_FINAL_1.pdf. Accessed 12 Feb 2015.
8. WHO. Guidelines for the Treatment of Malaria. In: Global Malaria Programme. 2nd ed. Geneva: World Health Organization; 2010. http://www.who.int/malaria/publications/atoz/9789241547925/en/. Accessed 12 Feb 2015.
9. Anthony MP, Burrows JN, Duparc S, Moehrle J, Wells TN. The global pipeline of new medicines for the control and elimination of malaria. Malar J. 2012;11:316.
10. Maude RJ, Woodrow CJ, White LJ. Artemisinin anti-malarials: preserving the “magic bullet.” Drug Dev Res. 2010;71:12–9.
11. Malawi Malaria Programme Performance Review: Aide Memoire. Roll Back Malaria. 2010. http://www.rollbackmalaria.org/files/files/countries/Malawi-The- malarial-program-performance-review-2010-Report.pdf. Accessed 12 Feb 2015.
12. Abukau B, Duah N, Quaye L, Quashie N, Koram K. Therapeutic efficacy of artemether-lumefantrine combination in the treatment of uncomplicated malaria among children under five years of age in three ecological zones in Ghana. Malar J. 2012;11:388.
13. Joseph D, Kabanywanyi AM, Hulser R, Premji Z, Minz OM, Mugittu K. Exploration of in vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in under fives in Tabora region, Tanzania. Malar J. 2013;12:260.
14. WHO. World malaria report 2012. Geneva: World Health Organization, Global Malaria Programme; 2012, 2015. http://www.who.int/malaria/publications/ world-malaria_report_2012/report/en/. Accessed 12 Feb 2015.
15. Wongsrichanalai C, Meshnick SR. Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia–Thailand border. Emerg Infect Dis. 2008;14:76–9.
16. Alker AP, Lim P, Sem R, Shah NK, Yi P, Bouth DM, et al. Pfcrt1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian–Thai border. Am J Trop Med Hyg. 2007;76:641–7.
17. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of artesinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359:2619–20.
18. Barclay VC, Smith RA, Findley JS. Surveillance considerations for malaria elimination. Malar J. 2012;11:304.
19. International Conference on Harmonization (ICH): Post-approval safety data management: definitions and standards for expedited reporting E2D. ICH: Current Step 4 Version. 2003. http://www.ich.org/fileadmin/Public_Web_Site/ ICH_products/Guidelines/Efficacy/E2D/Step4/E2D_Guideline.pdf. Accessed 12 Feb 2015.
20. WHO. Susceptibility of Plasmodium falciparum to anti-malarial drugs: global monitoring 1996-2004. Geneva: World Health Organization. 2005. http://www.who/bddc.who.int/publications/2005/9241593466_eng.pdf. Accessed 12 Feb 2015.
21. Eshetu T, Abdo N, Bedru KH, Fekadu S, Wieser A, Pritzl M, et al. Open-label trial with artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria three years after its broad introduction in Jimma Zone. Ethiopia Malar J. 2012;11:240.
22. Byakika-Kibirwa P, Lamorde M, Mayanja-Kizza H, Merry C, Colebunders B, Van Geertruyden JP. Update on the efficacy, effectiveness and safety of artesunate-lumefantrine combination therapy for treatment of uncomplicated malaria. Ther Clin Risk Manag. 2010;6:11–20.
23. Denis MB, Tsuyuoka R, Lim P, Lindegardh N, Yi P, Top SN, et al. Efficacy of artesunate-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in northwest Cambodia. Trop Med Int Health. 2006;11:1800–7.
24. ter Kuile F, White NJ, Holloway P, Pasvol G, Krishna S. Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol. 1993;76:85–95.
25. Angus BJ, Chotvanich K, Udomsangpetch R, White NJ. In vivo removal of malaria parasites from red blood cells without their destruction in acute falciparum malaria. Blood. 1997;90:2037–40.
26. Price RN, Nosten F, Luxemburger C, ter Kulle FO, Paquhun L, Chongsuwapanjiddhi T, et al. Effects of artesinin derivatives on malaria transmissibility. Lancet. 1996;347:1654–8.
27. Udomsangpetch R, Pipitporn B, Krishna S, Angus B, Puiktitayakamsuee S, Bates I, et al. Anti-malarial drugs reduce cytoadherence and retetaking Plasmodium falciparum. J Infect Dis. 1996;173:691–8.
28. Phyo AP, Nkorma S, Spoonakwana K, Ashley EA, Nair S, McGready R, et al. Emergence of artesinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012;379:1960–6.
29. Mayxay M, Khanthavong M, Chanthongthip O, Imwong M, Pongvongsa T, Bates I, et al. Multicentre, open-label, randomised, controlled clinical trial of artemisinin derivatives on malaria parasites from red blood cells without their destruction in acute falciparum malaria. Blood. 1997;90:2037–40.